[1] |
中国幽门螺杆菌根除与胃癌防控的专家共识意见(2019年, 上海)[J]. 中华消化杂志, 2019, 39(5): 310-315.
|
[2] |
Butt J, Lehtinen M, Öhman H, et al. Association of helicobacter pylori and autoimmune gastritis with stomach cancer in a cohort of young finnish women[J]. Gastroenterology, 2022, 163(1):305-307.e4.
doi: 10.1053/j.gastro.2022.03.012
URL
|
[3] |
Hooi JKY, Lai WY, Ng WK, et al. Global prevalence of helicobacter pylori infection: Systematic review and meta-analysis[J]. Gastroenterology, 2017, 153(2):420-429.
doi: 10.1053/j.gastro.2017.04.022
URL
|
[4] |
Fallone CA, Moss SF, Malfertheiner P. Reconciliation of recent helicobacter pylori treatment guidelines in a time of increasing resistance to antibiotics[J]. Gastroenterology, 2019, 157(1):44-53.
doi: S0016-5085(19)35704-X
pmid: 30998990
|
[5] |
柴永洪, 袁进国. 呋喃唑酮致双硫醒样反应误诊1例分析[J]. 中国误诊学杂志, 2007, 7(12):2789-2789.
|
[6] |
贺铁钢, 申育琳, 王晖. 口服呋喃唑酮后饮酒致严重双硫仑样反应一例[J]. 临床误诊误治, 2015, 28(3):113-114.
|
[7] |
刘晓红, 孙国良. 呋喃唑酮过量致神经精神症状[J]. 临床误诊误治, 2004, 17(1):62-62.
|
[8] |
陈桂英, 田云霄, 刘秀玲, 等. 长期正常剂量服用痢特灵致末梢神经炎3例[J]. 河北医科大学学报, 2005, 26(2):96-96.
|
[9] |
樊福强, 刘美萍, 刘志辉. 呋喃唑酮致多发性神经病1例[J]. 潍坊医学院学报, 2010, 32(6):404-404.
|
[10] |
关丽, 陈军, 武新安, 等. 呋喃唑酮致神经系统毒性及精神障碍的系统评价[J]. 中国新药与临床杂志, 2015, 34(6):436-440.
|
[11] |
李世林. 呋喃唑酮致高血压危象二例[J]. 临床误诊误治, 2000, 13(5):391-391.
|
[12] |
杨文瑾, 黄金叶, 游咏. 呋喃唑酮过量致直立性低血压1例[J]. 中国医院药学杂志, 2019, 39(11):1217-1218.
|
[13] |
杨士珍. 呋喃唑酮引起幼儿急性肝损害[J]. 药物不良反应杂志, 2009, 11(5):368.
|
[14] |
周海艳, 胡伏莲, 刘绍能. 呋喃唑酮引起全身皮肤剧烈疼痛的罕见表现一例[J]. 中华医学杂志, 2019, 99(22):1756-1757.
|
[15] |
Varma SK, Sutradhar S, Misra AK. Levofloxacin and furazolidone induced toxic epidermal necrosis[J]. Indian J Pharmacol, 2013, 45(6):625-626.
doi: 10.4103/0253-7613.121380
URL
|
[16] |
张丽丽, 施丽婕. 呋喃唑酮根除幽门螺旋杆菌出现不良反应2例[J]. 临床合理用药杂志, 2018, 11(13):118.
|
[17] |
汪平凡, 高虎云, 杨新叶, 等. 呋喃唑酮不良反应(附药疹祖孙三代一家系报告)[J]. 临床医学, 2008, 28(10):110-111.
|
[18] |
Yi DM, Yang TT, Chao SH, et al. Comparison the cost-efficacy of furazolidone-based versus clarithromycin-based quadruple therapy in initial treatment of Helicobacter pylori infection in a variable clarithromycin drug-resistant region, a single-center, prospective, randomized, open-label study[J]. Medicine (Baltimore), 2019, 98(6):e14408.
doi: 10.1097/MD.0000000000014408
URL
|
[19] |
Xie Y, Zhang Z, Hong J, et al. Furazolidone-containing triple and quadruple eradication therapy for initial treatment for Helicobacter pylori infection: A multicenter randomized controlled trial in China[J]. Helicobacter, 2018, 23(5):e12496.
doi: 10.1111/hel.12496
URL
|
[20] |
Zhuge L, Wang Y, Wu S, et al. Furazolidone treatment for Helicobacter Pylori infection: A systematic review and meta-analysis[J]. Helicobacter, 2018, 23(2):e12468.
doi: 10.1111/hel.12468
URL
|
[21] |
Liu A, Wang Y, Song Y, Du Y. Treatment with compound Lactobacillus acidophilus followed by a tetracycline- and furazolidone-containing quadruple regimen as a rescue therapy for Helicobacter pylori infection[J]. Saudi J Gastroenterol, 2020, 26(2):78-83.
|
[22] |
刘文忠, 谢勇, 陆红, 等. 第五次全国幽门螺杆菌感染处理共识报告[J]. 胃肠病学, 2017, 22(6): 346-360.
|
[23] |
刘鑫磊, 杨锦林, 赵颖. 含呋喃唑酮与四环素四联疗法根除幽门螺杆菌致急性溶血性贫血一例[J]. 华西医学, 2020, 35(2):247-248.
|
[24] |
赵娅, 郭嘉荣, 凌霄. 等. 呋喃唑酮所致药品不良反应的数据分析[J]. 中国药物滥用防治杂志, 2020, 26(06), 353-356.
|
[25] |
Song C, Qian X, Zhu Y, et al. Effectiveness and safety of furazolidone-containing quadruple regimens in patients with Helicobacter pylori infection in real-world practice[J]. Helicobacter, 2019, 24(4):e12591.
|
[26] |
De Francesco V, Ierardi E, Hassan C, et al. Furazolidone therapy for Helicobacter pylori: Is it effective and safe?[J]. World J Gastroenterol, 2009, 15(15):1914-1915.
doi: 10.3748/wjg.15.1914
URL
|
[27] |
国家药品监督管理局. 关于修订呋喃唑酮片说明书的公告[R]. 2018-43.
|